Targeting DNA repair pathways in prostate cancer
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers
['FUNDING_P01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10922777
This study is looking at whether a special combination of treatments can help men with non-castrate prostate cancer, especially those with certain genetic changes, by focusing on fixing DNA damage to improve their chances of recovery.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10922777 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the DNA damage repair (DDR) pathway can improve treatment outcomes for patients with non-castrate prostate cancer. The approach involves using a combination of therapies, including a PARP inhibitor, androgen deprivation therapy, and surgery, to enhance the effectiveness of treatment. The study aims to determine if these targeted therapies can lead to better responses and potentially cure prostate cancer in patients with specific genetic alterations. Patients will be enrolled in a flexible, randomized clinical trial to assess the effectiveness of this multimodal treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-castrate prostate cancer who have specific genetic alterations in the DNA damage repair pathway.
Not a fit: Patients with prostate cancer that does not have alterations in the DNA damage repair pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for patients with non-castrate prostate cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches, particularly in patients with castration-resistant prostate cancer treated with PARP inhibitors.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHER, HOWARD I — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: SCHER, HOWARD I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.